Literature DB >> 5448096

Melphalan and myeloma. Experience with a low-dose continuous regimen.

J R McArthur, J W Athens, M M Wintrobe, G E Cartwright.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1970        PMID： 5448096     DOI： 10.7326/0003-4819-72-5-665

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  3 in total

Review 1.  Antineoplastic and immunosuppressive drugs. II. Therapeutic uses.

Authors:  M D Cridland
Journal:  Drugs       Date:  1972       Impact factor: 9.546

2.  Plasma cell myeloma: response of melphalan-resistant patients to high-dose intermittent cyclophosphamide.

Authors:  D E Bergsagel; D H Cowan; R Hasselback
Journal:  Can Med Assoc J       Date:  1972-11-04       Impact factor: 8.262

3.  Treatment of plasma cell neoplasm with recombinant leukocyte A interferon and human lymphoblastoid interferon.

Authors:  R Ohno; Y Kodera; M Ogura; T Murase; N Emi; M Okumura; Y Morishita; E Nagura; S Minami; Y Morishima
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.